Your browser doesn't support javascript.
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Ohashi, Hirofumi; Hishiki, Takayuki; Akazawa, Daisuke; Kim, Kwang Su; Woo, Joohyeon; Shionoya, Kaho; Tsuchimoto, Kana; Iwanami, Shoya; Moriyama, Saya; Kinoshita, Hitomi; Yamada, Souichi; Kuroda, Yudai; Yamamoto, Tsukasa; Kishida, Noriko; Watanabe, Shinji; Hasegawa, Hideki; Ebihara, Hideki; Suzuki, Tadaki; Maeda, Ken; Fukushi, Shuetsu; Takahashi, Yoshimasa; Iwami, Shingo; Watashi, Koichi.
  • Ohashi H; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Hishiki T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Akazawa D; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Kim KS; Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan; Department of Science System Simulation, Pukyong National University, Busan, Republic of Korea.
  • Woo J; Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Shionoya K; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Applied Biological Science, Tokyo University of Science, Noda, 278-8510, Japan.
  • Tsuchimoto K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Iwanami S; Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Kinoshita H; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Yamada S; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Kuroda Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Yamamoto T; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Kishida N; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Watanabe S; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Hasegawa H; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo, 208-0011, Japan.
  • Ebihara H; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Maeda K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Fukushi S; Department of Virology I, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Iwami S; Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan; Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan; Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Ja
  • Watashi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan; Department of Applied Biological Science, Tokyo University of Science, Noda, 278-8510, Ja
Antiviral Res ; 205: 105372, 2022 09.
Article in English | MEDLINE | ID: covidwho-1914151
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence's impact on choosing optimal drug treatment.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Journal: Antiviral Res Year: 2022 Document Type: Article Affiliation country: J.antiviral.2022.105372

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Journal: Antiviral Res Year: 2022 Document Type: Article Affiliation country: J.antiviral.2022.105372